SG10201506909PA - Treatment of myocardial infarction using tgf - beta antagonists - Google Patents

Treatment of myocardial infarction using tgf - beta antagonists

Info

Publication number
SG10201506909PA
SG10201506909PA SG10201506909PA SG10201506909PA SG10201506909PA SG 10201506909P A SG10201506909P A SG 10201506909PA SG 10201506909P A SG10201506909P A SG 10201506909PA SG 10201506909P A SG10201506909P A SG 10201506909PA SG 10201506909P A SG10201506909P A SG 10201506909PA
Authority
SG
Singapore
Prior art keywords
tgf
treatment
myocardial infarction
beta antagonists
antagonists
Prior art date
Application number
SG10201506909PA
Inventor
Geoffrey Y Akita
Scott Lonning
Richard C Gregory Jr
Amelia B Kudej
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of SG10201506909PA publication Critical patent/SG10201506909PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
SG10201506909PA 2010-09-01 2011-09-01 Treatment of myocardial infarction using tgf - beta antagonists SG10201506909PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37931510P 2010-09-01 2010-09-01

Publications (1)

Publication Number Publication Date
SG10201506909PA true SG10201506909PA (en) 2015-10-29

Family

ID=44654454

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2013013875A SG187953A1 (en) 2010-09-01 2011-09-01 Treatment of myocardial infarction using tgf - beta antagonists
SG10201506909PA SG10201506909PA (en) 2010-09-01 2011-09-01 Treatment of myocardial infarction using tgf - beta antagonists

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2013013875A SG187953A1 (en) 2010-09-01 2011-09-01 Treatment of myocardial infarction using tgf - beta antagonists

Country Status (18)

Country Link
US (2) US20130330352A1 (en)
EP (1) EP2611831B1 (en)
JP (2) JP6377348B2 (en)
KR (1) KR101939965B1 (en)
CN (1) CN103201292B (en)
BR (1) BR112013004850B1 (en)
CA (1) CA2809568C (en)
CL (1) CL2013000586A1 (en)
ES (1) ES2715177T3 (en)
IL (1) IL225018A (en)
MX (1) MX354535B (en)
MY (1) MY165160A (en)
NZ (2) NZ608813A (en)
PL (1) PL2611831T3 (en)
RU (1) RU2637088C2 (en)
SG (2) SG187953A1 (en)
TR (1) TR201903101T4 (en)
WO (1) WO2012030394A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1008628A2 (en) * 2009-02-18 2016-03-01 Cormatrix Cardiovascular Inc method of treating or preventing cardiac arrhythmia in an individual
EP3415633B1 (en) * 2013-03-11 2020-10-28 Genzyme Corporation Engineered anti-tgf-beta antibodies and antigen-binding fragments
CN116655801A (en) 2013-08-22 2023-08-29 阿塞勒隆制药公司 TGF-beta receptor type II variants and uses thereof
CA3008162A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
CA2971186A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
CA2994413A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma, Inc. Methods for treating myeloproliferative disorders
RS64053B1 (en) * 2015-10-30 2023-04-28 Univ California Transforming growth factor-beta-responsive polypeptides and their methods for use
TW201726744A (en) * 2016-01-11 2017-08-01 奧托德里克有限公司 Composition, device, and method for detecting OLMESARTAN and improving compliance in treating hypertension
US20170218040A1 (en) * 2016-02-02 2017-08-03 Julio A. Camarero Palao Proteolically resistant cyclotides with angiotensin 1-7 like activity
US20190216943A1 (en) * 2016-08-11 2019-07-18 Precithera, Inc. Tgf-beta antagonist conjugates
LT3628049T (en) 2017-05-04 2023-08-25 Acceleron Pharma Inc. Tgf-beta receptor type ii fusion proteins and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3720353B2 (en) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル Multivalent and multispecific binding proteins, their production and use
DE69941267D1 (en) 1998-12-10 2009-09-24 Bristol Myers Squibb Co PROTEIN EQUIPMENT FOR ANTIBODY-NACHHAMMER AND OTHER BINDING PROTEINS
US7763580B2 (en) * 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
ES2527292T3 (en) 2004-03-31 2015-01-22 Genentech, Inc. Humanized anti-TGF-beta antibodies
AP2764A (en) * 2005-01-31 2013-09-30 Mylan Lab Inc Hydroxylated nebivolol metabolites
PL1850873T3 (en) * 2005-02-08 2019-06-28 Genzyme Corporation Antibodies to tgfbeta
CN102292124A (en) * 2009-01-26 2011-12-21 英特芒尼公司 Methods for treating acute myocardial infarctions and associated disorders
ITMI20110376A1 (en) 2011-03-10 2012-09-11 Wilic Sarl FLUID COOLED AIRBRUSHER

Also Published As

Publication number Publication date
NZ624382A (en) 2015-05-29
CA2809568A1 (en) 2012-03-08
KR101939965B1 (en) 2019-01-18
KR20130111550A (en) 2013-10-10
BR112013004850B1 (en) 2020-04-07
BR112013004850A2 (en) 2016-05-31
ES2715177T3 (en) 2019-06-03
CL2013000586A1 (en) 2013-08-30
EP2611831B1 (en) 2018-12-12
JP2017193543A (en) 2017-10-26
JP6377348B2 (en) 2018-08-22
CN103201292A (en) 2013-07-10
CN103201292B (en) 2016-09-14
MX354535B (en) 2018-03-09
IL225018A (en) 2017-11-30
WO2012030394A1 (en) 2012-03-08
AU2011296574A1 (en) 2013-03-21
EP2611831A1 (en) 2013-07-10
SG187953A1 (en) 2013-03-28
MY165160A (en) 2018-02-28
US20170233465A1 (en) 2017-08-17
CA2809568C (en) 2019-06-11
JP2013542179A (en) 2013-11-21
RU2013114365A (en) 2014-10-10
TR201903101T4 (en) 2019-03-21
US20130330352A1 (en) 2013-12-12
NZ608813A (en) 2014-11-28
PL2611831T3 (en) 2019-05-31
AU2011296574B2 (en) 2015-12-03
US10633437B2 (en) 2020-04-28
RU2637088C2 (en) 2017-11-29
MX2013002390A (en) 2013-08-27

Similar Documents

Publication Publication Date Title
SG10201506909PA (en) Treatment of myocardial infarction using tgf - beta antagonists
AP3391A (en) 2-Amino-4-arylthiazole compounds as TROA1 antagonists
EP2627178A4 (en) Quinazolinone-type compounds as crth2 antagonists
HRP20211969T1 (en) Pharmaceutical composition of carbetocin
AP3030A (en) Propynylaminoindan transdermal compositions
HK1175171A1 (en) Compounds as bradykinin b1 antagonists b1
EP2526772A4 (en) Multifunctional surface treatment composition
PL2534302T3 (en) Surface treatment composition
GB201005927D0 (en) Improved composition
IL222072A (en) Composition for treatment of essential thrombocythemia
LT2460509T (en) Composition for the treatment of warts
EP2634213A4 (en) Olefin composition
TWM401347U (en) Improved structure of brush
HK1160777A1 (en) Novel use of neohesperidoside
ZA201209076B (en) Laundry treatment composition
TWM389753U (en) Improved structure of handle
HK1133781A2 (en) One kind of toothbrushes
HU1000688D0 (en) Use of trifluoro-phal
HK1200443A1 (en) Compounds as bradykinin b1 antagonists b1
TWM390770U (en) Preheater of endoscope
TWM385541U (en) Improved structure of container
TWM386872U (en) Improvement of mop structure
TWM400763U (en) Improved structure of cold-accumulating cravats
TWM388315U (en) Improved structure of hemoclip
TWM390721U (en) Sharing cup